Clinical trials of multiple sclerosis monitored with enhanced MRI: New sample size calculations based on large data sets

M. P. Sormani, D. H. Miller, G. Comi, F. Barkhof, M. Rovaris, P. Bruzzi, M. Filippi

Research output: Contribution to journalArticle

Abstract

Objective - A new parametric simulation procedure based on the negative binomial (NB) model was used to evaluate the sample sizes needed to achieve optimal statistical powers for parallel groups (with (PGB) and without (PG) a baseline correction scan). It was also used for baseline versus treatment (BVT) design clinical trials in relapsing-remitting (RR) and secondary progressive (SP) multiple sclerosis (MS), when using the number of new enhancing lesions seen on monthly MRI of the brain as the measure of outcome. Methods - MRI data obtained from 120 untreated patients with RRMS selected for the presence of MRI activity at baseline, 66 untreated and unselected patients with RRMS, and 81 untreated and unselected patients with SPMS were fitted using an NB distribution. All these patients were scanned monthly for at least 6 months and were all from the placebo arms of three large scale clinical trials and one natural history study. The statistical powers were calculated for durations of follow up of 3 and 6 months. Results - The frequency of new enhancing lesions in patients with SPMS was lower, but not significantly different, from that seen in unselected patients with RRMS. As expected, enhancement was more frequent in patients with RRMS selected for MRI activity at baseline than in the other two patient groups. As a consequence, the estimated sample sizes needed to detect treatment efficacy in selected patients with RRMS were smaller than those of unselected patients with RRMS and those with SPMS. Baseline correction was also seen to reduce the sample sizes of PG design trials. An increased number of scans reduced the sample sizes needed to perform BVT trials, whereas the gain in power was less evident in PG and PGB trials. Conclusion - This study provides reliable estimates of the sample sizes needed to perform MRI monitored clinical trials in the major MS clinical phenotypes, which should be useful for planning future studies.

Original languageEnglish
Pages (from-to)494-499
Number of pages6
JournalJournal of Neurology, Neurosurgery and Psychiatry
Volume70
Issue number4
DOIs
Publication statusPublished - Apr 2001

Keywords

  • Magnetic resonance imaging
  • Multiple sclerosis
  • Sample size calculations
  • Treatment trials

ASJC Scopus subject areas

  • Neuropsychology and Physiological Psychology
  • Neuroscience(all)
  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'Clinical trials of multiple sclerosis monitored with enhanced MRI: New sample size calculations based on large data sets'. Together they form a unique fingerprint.

  • Cite this